Covered recipient · General Payments record
NICHOLAS E ENGELBRECHT
Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist
General Payments · PY2018–2024
$1,858.28
- Reported across 63 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $605.14 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $152.46 | 2 |
| Genentech, Inc. | $141.15 | 1 |
| Astellas Pharma US Inc | $104.71 | 4 |
| Genentech USA, Inc. | $80.77 | 3 |
| ABBVIE INC. | $54.88 | 3 |
| UCB, Inc. | $48.10 | 2 |
| Harrow Eye, LLC | $23.07 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.37 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103693556 | CMS |
| ABBVIE INC. | $20.02 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103693558 | CMS |
| ABBVIE INC. | $18.49 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103693560 | CMS |
| Astellas Pharma US Inc | $20.21 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139337724 | CMS |
| Astellas Pharma US Inc | $25.45 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139282564 | CMS |
| Astellas Pharma US Inc | $33.77 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139402525 | CMS |
| Astellas Pharma US Inc | $25.28 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139436478 | CMS |
| Genentech USA, Inc. | $26.10 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133080718 | CMS |
| Genentech USA, Inc. | $31.63 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133080722 | CMS |
| Genentech USA, Inc. | $23.04 | 10/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133080726 | CMS |
| Genentech, Inc. | $141.15 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133080730 | CMS |
| Harrow Eye, LLC | $23.07 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145602332 | CMS |
| Regeneron Healthcare Solutions, Inc. | $125.00 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114043795 | CMS |
| Regeneron Healthcare Solutions, Inc. | $27.46 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114043797 | CMS |
| UCB, Inc. | $22.65 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143197823 | CMS |
| UCB, Inc. | $25.45 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143197828 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.